Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A targeted therapy for a tough-to-treat lung cancer keeps delivering. Updated data from the TRUST-I and TRUST-II trials show taletrectinib achieved an 89.8% response rate in treatment-naive patients with ROS1-positive NSCLC, with median progression-free survival exceeding 46 months. Even patients who had already received a prior TKI saw meaningful responses, with a 55.8% response rate.
Nearly three years of follow-up data from the phase 2 TRUST-I and TRUST-II trials confirm that taletrectinib is a strong contender in the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Presented at the 2026 World Conference on Lung Cancer, the pooled analysis of 270 patients showed high and durable responses across both treatment-naive and previously treated patients — regardless of ROS1 fusion partner type or prior chemotherapy exposure.
The safety profile remained consistent with earlier reports, with no new signals emerging. While dose interruptions were common (42.7% of patients), treatment discontinuations due to adverse events were relatively low at 8.5%, suggesting the drug is generally well-tolerated over the long term.
By the Numbers:
Why it matters: ROS1-positive NSCLC is a relatively rare but aggressive subtype. These results reinforce taletrectinib's potential as a best-in-class option, particularly for first-line use, where its durability could meaningfully extend survival.
